Shenzhen YHLO Biotech CoSHSE:688575 +0.33%64 ROE % is 2.65% as of Mar. 2026, which is 81% below its 10-year median of 14.27. GuruFocus rates SHSE:688575 with a GF Score™ of 64/100 and a GF Value™ of ¥14.47 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 797 Medical Devices & Instruments companies, Shenzhen YHLO Biotech Co ranks worse than 53.2% on this metric.
The historical rank and industry rank for Shenzhen YHLO Biotech Co's ROE % or its related term are showing as below:
SHSE:688575'
s ROE % Range Over the Past 10 Years
Min: 0.86 Med: 14.27 Max: 51.34
Current: 1.15
During the past 9 years, Shenzhen YHLO Biotech Co's highest ROE % was 51.34%. The lowest was 0.86%. And the median was 14.27%.
SHSE:688575's ROE % is ranked worse than 53.2% of 797
companies
in the Medical Devices & Instruments industry
Industry Median: 2.4
vs SHSE:688575: 1.15
Shenzhen YHLO Biotech Co (SHSE:688575) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Shenzhen YHLO Biotech Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhen YHLO Biotech Co ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shenzhen YHLO Biotech Co's ROE % distribution charts can be found below:
* The bar in red indicates where Shenzhen YHLO Biotech Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Shenzhen YHLO Biotech Co (SHSE:688575) has a ROE % of 2.65% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Shenzhen YHLO Biotech Co and its competitors. This is 81% below median its historical median of 14.27. Over the past decade, Shenzhen YHLO Biotech Co's ROE % has ranged from 0.86 to 51.34. According to the industry distribution chart, Shenzhen YHLO Biotech Co ranks #424 out of 797 companies in the Medical Devices & Instruments industry, placing it in the top 53.2%.
Is Shenzhen YHLO Biotech Co's ROE % too high?
Shenzhen YHLO Biotech Co's current ROE % of 2.65% is 81% below median its 10-year median of 14.27. Over the past 10 years, this metric has ranged from a low of 0.86 to a high of 51.34. The Medical Devices & Instruments industry median ROE % is 2.40. Shenzhen YHLO Biotech Co's value of 2.65% is 10.4% above this industry median. Based on the distribution chart, Shenzhen YHLO Biotech Co ranks #424 out of 797 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Shenzhen YHLO Biotech Co has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shenzhen YHLO Biotech Co's ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shenzhen YHLO Biotech Co ranks #424 out of 797 companies for ROE %. This places Shenzhen YHLO Biotech Co in the lower half of its industry. The industry median ROE % is 2.40. Shenzhen YHLO Biotech Co's value of 2.65% is 10.4% above this benchmark. Historically, Shenzhen YHLO Biotech Co's own ROE % has ranged from 0.86 to 51.34 over the past decade. While the company's 10-year median is 14.27 vs. the industry median of 2.40, Shenzhen YHLO Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.40, based on 797 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shenzhen YHLO Biotech Co's current ROE % of 2.65% is 10.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Shenzhen YHLO Biotech Co and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhen YHLO Biotech Co's current ROE % is 2.65%, which is 81% below median its own 10-year median of 14.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen YHLO Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhen YHLO Biotech Co (SHSE:688575) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥14.47, compared to a current price of ¥9.20 — trading 36.4% below its estimated fair value. The current ROE % is 2.65%, which is 81% below median its 10-year median of 14.27 and 10.4% above the Medical Devices & Instruments industry median of 2.40. Shenzhen YHLO Biotech Co's overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Shenzhen YHLO Biotech Co (SHSE:688575), the current ROE % is 2.65% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhen YHLO Biotech Co (SHSE:688575) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhen YHLO Biotech Co stock appears to be undervalued.
The current stock price of ¥9.20 is trading 36.4% below its estimated GF Value™ of ¥14.47.
GuruFocus considers Shenzhen YHLO Biotech Co to be Significantly Undervalued.
Key valuation signals for SHSE:688575:
ROE %: 2.65% (81% below median its 10-year median of 14.27)
GF Value™: ¥14.47 vs. price of ¥9.20 (36.4% below fair value)
Industry Position: 10.4% above the Medical Devices & Instruments median (#424 of 797)
No single metric tells the full story. See the SHSE:688575 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shenzhen YHLO Biotech Co Ltd is engaged in the research, development, production and sales of in vitro diagnostic instruments and supporting reagents based on chemiluminescence immunoassay. Its product portfolio includes solutions based on technologies such as chemiluminescence, biochemistry, indirect immunofluorescence, immunoblotting, fluorescent immunochromatography, and colloidal gold immunochromatography. Its products are used in diagnostic applications including autoimmunity, reproductive health, infection, liver disease, and respiratory disease testing, and are supplied to healthcare institutions and testing centers.
64GF Score
Get the complete analysis for SHSE:688575
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688575 has been successfully added to your 
